Open AccessCost-effectiveness analysis of colon cancer treatments from MOSIAC and No. 16968 trials
Author(s) -
Feng Wen,
Ke Yao,
Zedong Du,
Xiaofeng He,
Pengfei Zhang,
Ruilei Tang,
Li Qiu
Publication year - 2014
Publication title -
world journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.427
H-Index - 155
eISSN - 2219-2840
pISSN - 1007-9327
DOI - 10.3748/wjg.v20.i47.17976
Subject(s) - medicine , colorectal cancer , regimen , cost effectiveness analysis , quality adjusted life year , adverse effect , adjuvant , fluorouracil , cost effectiveness , oncology , chemotherapy , surgery , cancer , risk analysis (engineering)
To compare XELOX and FOLFOX4 as colon cancer adjuvant chemotherapy based on MOSAIC and No. 16968 trails from Chinese cost-effectiveness perspective.